Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant [Phase 3]
Pfizer is conducting a Phase 3 trial comparing elranatamab to lenalidomide in patients with newly diagnosed multiple myeloma after autologou…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel [Phase 2]
Phase 2 clinical trial update evaluating nivolumab in multiple myeloma patients who previously received idecabtagene vicleucel (ide-cel).
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study [NA]
The document reports a completed descriptive pilot study evaluating dermo-cosmetic products to treat skin and nail toxicity in multiple myel…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma [Phase 1, Phase 2]
Update on a Phase 1/2 clinical trial evaluating a four-drug combination (carfilzomib, lenalidomide, dexamethasone, belantamab mafodotin) for…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) [Phase 2]
A Phase 2 study evaluating CyBorD (cyclophosphamide, bortezomib, dexamethasone) plus daratumumab in people with Monoclonal Gammopathy of Ren…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Clinical Study of SHR-9539 in Patients With Multiple Myeloma [Phase 1]
A Phase 1 clinical trial of SHR-9539 in patients with multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial comparing Etentamig plus daratumumab versus daratumumab, lenalidomide, and dexamethasone in adults with new…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) [Phase 4]
Pfizer's Phase 4 post-trial access study for Elranatamab in participants with multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Pre-malignant States to Hematologic Malignancies in Firefighters
A Wake Forest trial investigates progression from pre-malignant hematologic states to blood cancers in firefighters and is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: PET Imaging Study of 68Ga-NB381 in Multiple Myeloma [EARLY_Phase 1]
Clinical trial update describes a PET imaging study of 68Ga-NB381 for multiple myeloma in early Phase 1, currently recruiting. Sponsor: Peki…
-
EMA withdrawal · 2026-04-15EMA Withdrawn: Bortezomib Hospira (bortezomib) — Pfizer Europe MA EEIG
The EMA has withdrawn the European marketing authorization for Bortezomib Hospira (bortezomib) by Pfizer Europe MA EEIG, affecting treatment…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma [Phase 1]
Phase 1 study evaluating CS1-CAR T cell therapy after chemotherapy in patients with relapsed or refractory CS1-positive multiple myeloma is …
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating the combination of elotuzumab and lenalidomide after stem cell transplantation in patients with newly diagnosed mul…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating a two-arm regimen for relapsed or refractory multiple myeloma using daratumumab, bortezomib, and dexamethasone foll…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide [Phase 1, Phase 2]
This registry entry describes a Phase 1/2 clinical trial at University of Alabama at Birmingham evaluating combination regimens that include…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma [Phase 2]
Phase II clinical trial evaluating salvage radiation therapy after BCMA CAR-T therapy in relapsed/refractory multiple myeloma. The study is …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy [NA]
This clinical trial update describes a study exploring voice as a way to monitor side effects in people receiving CAR T-cell therapy, includ…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. [Phase 2]
Phase 2 study evaluating daratumumab in combination with teclistamab or talquetamab for frail patients with newly diagnosed multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab [Phase 2]
A Phase 2 clinical trial update notes that participants who previously enrolled in an elotuzumab study may continue receiving treatment, and…
-
CLINICAL_TRIALS withdrawal · 2026-04-15Clinical Trial Update: Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial of Selvigaltin in combination with standard of care for relapsed/refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of carfilzomib-based regimens (CCyd or CRd) followed by autologous stem cell trans…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) [Phase 3]
Phase 3 clinical trial comparing BMS-986393 to standard regimens in adults with relapsed or refractory and lenalidomide-exposed multiple mye…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma [Phase 2]
Phase 2 trial evaluating the combination of cilta-cel (ciltacabtagene autoleucel) and talquetamab in high-risk multiple myeloma. The study s…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
This clinical trial update describes biospecimen procurement for the Center for Immuno-Oncology immunotherapy protocols. It covers recruitin…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma [Phase 3]
Phase 3 trial comparing fixed-duration versus continuous anti-CD38 monoclonal antibody therapy in transplant-ineligible older adults with ne…